Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly.

Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval making it the first ...

Johnson & Johnson JNJ announced that the FDA approved its precision therapy, Akeega (niraparib and abiraterone acetate ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

Those with prostate cancer that returns after surgery or radiation—and typically face a high risk of the disease spreading and death—could benefit from a new drug combination. A Cedars-Sinai Medical ...

In a recent interview with CURE, Dr. Kai Tsao broke down current treatment advancements for patients with prostate cancer.

Oct. 21, 2025 – A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to unprecedented results of a drug treatment trial in men whose ...

Scientists at the Herbert Irving Comprehensive Cancer Center (HICCC) have discovered a key mechanism that makes prostate cancer cells resistant to the latest drugs used to treat them. Their findings, ...

Adding the drug enzalutamide to standard hormone therapy reduced deaths by more than 40% in men with recurrent prostate cancer. The international study, published in The New England Journal of ...

So far, “the only established risk factors for prostate cancer are advancing age, African ancestry, and a family history of ...

A new drug combination may benefit men whose prostate cancer has returned after primary surgery or radiation therapy. Pairing enzalutamide, an androgen receptor blocker, with the hormone therapy drug ...